Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Significance of Persistent Systemic Support in the Clinical Course of Delayed Post-hypoxic Leukoencephalopathy Following Severe Coronavirus Disease 2019.
Kawasaki J, Mato N, Fujii H, Miura K, Mashiko T, Katayama S, Yamanouchi Y, Sato M, Takasaki T, Takigami A, Hisata S, Nunomiya S, Hagiwara K, Maemondo M. Kawasaki J, et al. Among authors: maemondo m. Intern Med. 2024 Apr 15;63(8):1167-1172. doi: 10.2169/internalmedicine.1412-22. Epub 2024 Feb 1. Intern Med. 2024. PMID: 38296478 Free PMC article.
A step towards tackling chemotherapy-induced peripheral neuropathy (CIPN).
Maemondo M, Cho K, Saikawa H, Hashimoto T, Katagiri H, Owada Y, Yakuwa K, Fujimura I, Utsumi Y, Akiyama M, Nagashima H, Takahashi F. Maemondo M, et al. Ann Palliat Med. 2024 Nov;13(6):1554-1555. doi: 10.21037/apm-24-113. Ann Palliat Med. 2024. PMID: 39632821 Free article. No abstract available.
A phase II study of daily carboplatin plus irradiation followed by durvalumab therapy for older adults (≥75 years) with unresectable III non-small-cell lung cancer and performance status of 2: NEJ039A.
Mouri A, Kisohara A, Morita R, Ko R, Nakagawa T, Makiguchi T, Isobe K, Ishikawa N, Kondo T, Akiyama M, Bessho A, Honda R, Yoshimura K, Kagamu H, Kato S, Kobayashi K, Kaira K, Maemondo M. Mouri A, et al. Among authors: maemondo m. ESMO Open. 2024 Oct;9(10):103939. doi: 10.1016/j.esmoop.2024.103939. Epub 2024 Oct 11. ESMO Open. 2024. PMID: 39395258 Free article. Clinical Trial.
First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.
Imai H, Kijima T, Azuma K, Kishi K, Saito H, Yamaguchi T, Tanizaki J, Yoneshima Y, Fujita K, Watanabe S, Kitazono S, Fukuhara T, Hataji O, Toi Y, Mizutani H, Hamakawa Y, Maemondo M, Ohsugi T, Suzuki K, Horinouchi H, Ohe Y. Imai H, et al. Among authors: maemondo m. Jpn J Clin Oncol. 2024 Apr 6;54(4):452-462. doi: 10.1093/jjco/hyad195. Jpn J Clin Oncol. 2024. PMID: 38271158 Free PMC article.
Characteristics and prognostic analysis of patients with detected KRAS mutations in resected lung adenocarcinomas by peptide nucleic acid-locked nucleic acid polymerase chain reaction (PNA-LNA PCR) clamp method.
Hashimoto T, Owada Y, Katagiri H, Yakuwa K, Tyo K, Sugai M, Fuzimura I, Utsumi Y, Akiyama M, Nagashima H, Terasaki H, Yanagawa N, Saito H, Sugai T, Maemondo M. Hashimoto T, et al. Among authors: maemondo m. Transl Lung Cancer Res. 2023 Sep 28;12(9):1862-1875. doi: 10.21037/tlcr-23-15. Epub 2023 Sep 15. Transl Lung Cancer Res. 2023. PMID: 37854155 Free PMC article.
155 results